The new pill, which targets the genetics of influenza viruses, has shown that it can reduce fever and respiratory symptoms in lab animals, as well as reducing the overall amount of virus in their bodies, researchers report.
Preparations are underway for human trials of the “next-generation” drug, EIDD-2801, said senior researcher Richard Plemper, a professor with the Institute of Biomedical Sciences at Georgia State University.
Several antiviral drugs already are on the market for influenza, the most widely known of which is Tamiflu.
The new drug appears to have one significant advantage over them, Plemper said — it seems to block attempts by the wily flu virus to mutate and become drug-resistant.
Read more at WebMD…